With earnings scheduled for the 23rd, Viking Therapeutic’s (NASDAQ: VKTX) first-quarter investor call is expected to center around key pipeline updates.
The spotlight will be on three clinical candidates: VK2735 (targeting obesity), VK2809 (for non-alcoholic steatohepatitis, or NASH), and VK0214 (for X-linked adrenoleukodystrophy, or X-ALD).
Our primary interest lies in VK2735, given our broader thesis that obesity treatments — and the transformative effects of weight loss — represent a powerful and growing trend in the consumer health space.
Founded in 2012, Viking is a U.S.-based biopharmaceutical company. One benchmark in this space is tirzepatide, a dual GLP-1/GIP receptor agonist approved by the FDA and marketed under the brand names Mounjaro® and Zepbound® in multiple dosages and formulations.
While we wait for the earnings report to be posted along with the forward guidance predictions, the chart looks interesting.
For starters, VKTX had a classic reversal bottom the week of April 7th.
Secondly, it outperforms the benchmark on the Leadership indicator.
Thirdly, the momentum, while not above its 50-DMA on real motion, is getting closer.
The weekly chart is also interesting.
VKTX is in Distribution and not a Bear Phase.
Most interesting is the 200-week moving average (green), which is a huge support area for price.
The price is also trading where it was at the end of 2023, before it exploded up to $100 and peaked.
While some patience is required, a weekly close above $24.50 is a good start.
The risk is then nominal, and the reward can be more than 4-5 times the risk.
Twitter: @marketminute
The author may have a position in mentioned securities at the time of publication. Any opinions expressed herein are solely those of the author and do not represent the views or opinions of any other person or entity.
